Imidazolonylquinoline compounds and therapeutic uses thereof

Patent metadata

Field	Value
Publication number	US-12344604-B2
Application number	US-202017442703-A
Country	US
Kind code	B2
Filing date	Mar 25, 2020
Priority date	Mar 27, 2019
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

Atropisomers, solid forms, salt forms, and deuterated derivatives of the ATM inhibitor 8-(1,3-Dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydroimidazo[4,5-c]quinolin-2-one as well as compositions thereof are provided. The stable atropisomers do not interconvert and are represented by the following formulae.

First claim

The invention claimed is:

1. A compound, represented by the following formula

or pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, comprising: the compound or pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable excipient.

3. Compound 1 according to claim 1 .

4. A pharmaceutically acceptable salt of Compound 1 according to claim 1 , wherein the pharmaceutically acceptable salt of Compound 1 is selected from the group consisting of Compound 1 fumarate, Compound 1 napsylate, and Compound 1 edisylate.

5. A solid anhydrous form of Compound 1 according to claim 1 .

6. The solid anhydrous form of Compound 1 according to claim 5 , wherein one or more peaks in a powder X-ray diffraction pattern is selected from those at about 7.3, about 9.6, about 11.1, about 12.0, about 12.7, and about 16.2 degrees 2-theta ±0.2 degrees 2-theta.

7. The solid anhydrous form of Compound 1 according to claim 5 , wherein the solid anhydrous form of Compound 1 has a monoclinic crystal system and a P2 1 space group and/or the following parameters of its unit cell:

a
 7.457 Å
α
90.0°

b
15.982 Å
β
90.0°

c
18.246 Å
γ
90.0°

V
  2174.5 Å 3 .

8. A pharmaceutical composition, comprising:
the solid anhydrous form of Compound 1 according to claim 5 , and a pharmaceutically acceptable excipient.

Assignees

• Merck Patent Gmbh

Inventors

• Fuchss Thomas
• Becker Axel
• Kubas Holger
• Graedler Ulrich

Classifications

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61K31/4745

  condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48) · CPC title

• A61P35/02

  specific for leukemia · CPC title